Pacira BioSciences
PCRX
231 hedge funds and large institutions have $2.06B invested in Pacira BioSciences in 2019 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 65 increasing their positions, 73 reducing their positions, and 30 closing their positions.
123% more call options, than puts
Call options by funds: $5.71M | Put options by funds: $2.57M
70% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 30
20% more capital invested
Capital invested by funds: $1.72B → $2.06B (+$341M)
9% more funds holding
Funds holding: 211 → 231 (+20)
0.6% more ownership
Funds ownership: 108.38% → 108.97% (+0.6%)
11% less repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 73
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
+$32.8M |
| 2 |
Renaissance Technologies
New York
|
+$24.7M |
| 3 |
SCM
Spyglass Capital Management
San Francisco,
California
|
+$17M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$16.2M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$11.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$60.9M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$16.8M |
| 3 |
Millennium Management
New York
|
-$15M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$14M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$12.7M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KC
251
Kepos Capital
New York
| – | -$173K | -4,537 | Closed |
|
|
CAC
252
Cowen and Company
New York
| – | -$151K | -3,979 | Closed |
|
|
TRCT
253
Tower Research Capital (TRC)
New York
| – | -$97K | -2,551 | Closed |
|
|
PHK
254
Point72 Hong Kong
Hong Kong
| – | -$47K | -1,239 | Closed |
|
255
Acadian Asset Management
Boston,
Massachusetts
| – | -$9K | -249 | Closed |
|
|
EW
256
Evoke Wealth
Los Angeles,
California
| – | -$8.64K | -227 | Closed |
|
|
CFGS
257
Concourse Financial Group Securities
Birmingham,
Alabama
| – | -$2K | -47 | Closed |
|
|
JG
258
Jefferies Group
New York
| – | -$1K | -35 | Closed |
|
259
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$1K | -29 | Closed |
|
|
SFS
260
Sowell Financial Services
North Little Rock,
Arkansas
| – | -$849 | -20 | -65% |
|
|
OPS
261
Orion Portfolio Solutions
Omaha,
Nebraska
| – | +$127 | +3 | New |
|
PCRX Hedge Fund Activity: Q4 2019 in Review
231 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q4 2019, worth a combined $2.06B — up 20% from $1.72B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new PCRX positions and 30 closed out — a net gain of 21 holders — while 65 added to existing stakes and 73 trimmed.
The largest buyer was HealthCor Management, opening a new position worth an estimated $32.8M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $60.9M sold.
- 231 institutional investors held Pacira BioSciences (PCRX) as of Q4 2019, up from 211 in Q3 2019.
- Funds reported $2.06B of Pacira BioSciences stock for Q4 2019, up 20% quarter-over-quarter.
- 51 funds opened new Pacira BioSciences positions in Q4 2019 and 30 closed out, a net change of +21 holders.
- The largest Pacira BioSciences buyer in Q4 2019 was HealthCor Management, an estimated $32.8M added.
- The largest Pacira BioSciences seller in Q4 2019 was Avoro Capital Advisors, an estimated $60.9M sold.
Based on aggregated 13F filings for Q4 2019.